Alkermes plc research snapshot
ALKS AI stock analysis currently reads Alkermes plc as a commercial neuroscience company with established products in addiction and psychiatry, a new sleep medicine franchise after the Avadel acquisition, and a pipeline led by the orexin 2 receptor agonist alixorexton. The latest verified close was $51.94 on July 10, 2026, and the reported market capitalization was about $8.69 billion. Alkermes generated $1.476 billion of revenue and $241.7 million of GAAP net income in 2025, while Q1 2026 revenue reached $392.9 million but GAAP net loss was $66.5 million after the acquisition. The central question is whether LUMRYZ and alixorexton can offset royalty declines and support the new debt load. This page uses scenario ranges, not a certain price prediction, and is for informational use only, not investment advice.
Current price
$51.94 close on July 10, 2026
Market cap
$8.69 billion reported, with $8.66 billion independently calculated from $51.94 and 166.68 million shares
AI score
63 / 100
Rating
Profitable neuroscience platform with sleep medicine upside, but acquisition leverage and patent risk limit certainty
Trend status
Medium-term bullish above the 200-day average, with short-term momentum extended and price near the 50-day average
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Alkermes develops, manufactures, and commercializes neuroscience medicines. Its proprietary portfolio includes VIVITROL, ARISTADA, LYBALVI, and LUMRYZ, while licensed products add manufacturing and royalty revenue. | High |
| Moat | The strongest defenses are long-acting formulation technology, regulatory and manufacturing know-how, patents, physician relationships, and design of medicines for difficult-to-treat conditions. Network effects are limited and generic competition remains a real threat. | Medium-high |
| Management | Richard Pops is scheduled to retire as CEO on July 31, 2026, with COO Blair Jackson appointed to succeed him on August 1. The management test is Avadel integration, debt repayment, clinical capital allocation, and a smooth leadership transition. | Medium-high |
| Financial trend | FY2025 revenue was $1.476 billion, GAAP net income was $241.7 million, operating cash flow was $520.8 million, and free cash flow was about $480.3 million. Q1 2026 revenue grew to $392.9 million, but acquisition accounting and higher investment produced a $66.5 million GAAP loss. | High |
| Valuation | At $51.94, the stock was about 36.3x FY2025 diluted GAAP EPS, 4.94x book value, and 18.2x FY2025 free cash flow per share. StockAnalysis showed a forward PE near 30.5x, so the price requires continued earnings recovery after the Avadel transaction. | High data confidence |
| Technical trend | The July 10 close was below the July 6 50-day simple moving average near $52.97 but above the 200-day average near $45.65. RSI near 65 and a positive MACD showed constructive momentum, while the 52-week high near $55.28 marked nearby supply. | Medium |
| Risk level | Risk is medium-high because Alkermes has new acquisition debt, a future CEO change, clinical and regulatory uncertainty, product concentration, VIVITROL generic risk, and declining legacy royalty revenue. | High |
| AI confidence | Data confidence is high for reported historical figures and disclosed transaction terms. Forecast confidence is medium because 2026 GAAP earnings are distorted by acquisition accounting and the pipeline remains event-driven. | High data, medium forecast |
| Investment certainty | ALKS is a conditional commercial and pipeline compounder rather than a high-certainty defensive stock. The thesis needs LUMRYZ growth, debt reduction, stable psychiatry products, and credible alixorexton development. | Medium |
ALKS AI stock forecast
The ALKS AI stock forecast uses a transparent three-year scenario model starting from FY2025 diluted GAAP EPS of $1.43. The financial_rigor.py model used 20%, 10%, and negative 15% annual EPS growth with terminal multiples of 35x, 28x, and 18x, producing approximately $86.50, $53.30, and $15.80. The starting EPS is reported, but the path is uncertain because Avadel acquisition accounting affects 2026 GAAP earnings.
$75 to $95
More likely if 2026 revenue lands near or above the company range of $1.73 billion to $1.84 billion, LUMRYZ gains patients without excessive selling costs, proprietary psychiatry products remain resilient, operating cash flow pays down debt, and alixorexton continues to produce strong Phase 3 evidence.
$45 to $65
More likely if LUMRYZ adds meaningful revenue, VIVITROL and LYBALVI grow moderately, royalty revenue continues to decline, acquisition costs fade, debt is reduced over time, and the market values normalized earnings near the high 20s PE range.
$12 to $25
More likely if LUMRYZ integration disappoints, VIVITROL generic competition arrives faster or erodes pricing, clinical trials fail, LYBALVI litigation or competition weakens sales, debt repayment limits R&D, or investors apply a lower multiple to reduced earnings.
ALKS AI technical analysis
ALKS AI technical analysis uses the July 10, 2026 closing price and the latest technical snapshot reviewed before the July 12 cutoff. Investing.com reported a July 6 RSI(14) of 65.478, MACD of 0.44, a 50-day simple moving average near $52.97, and a 200-day simple moving average near $45.65. The signal was constructive but price was close to the 52-week high, so levels should be treated as zones rather than exact predictions.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $51.94 | StockAnalysis closing snapshot for July 10, 2026. The market-cap page showed a closely matching $51.92 reference. |
| Immediate support | $50.98 to $51.72 | The July 1 intraday low was $50.98 and the close was $51.72 in the company historical price lookup. |
| Secondary support | $45.65 to $46.00 | The July 6 Investing.com 200-day simple moving average was near $45.65. A break below this area would weaken the medium-term trend. |
| Pivot resistance | $53.68 to $54.03 | Investing.com classic and Fibonacci pivot references placed the central pivot near $53.68 and upper references near $54.03 in the reviewed snapshot. |
| Major resistance | $55.28 | Investing.com listed the 52-week high near $55.28. A higher-volume close above that level would mark a new breakout attempt. |
| Moving averages | 50-day about $52.97; 200-day about $45.65 | Investing.com values dated July 6, 2026. Other feeds may update at different times. |
| Momentum | RSI 65.478; MACD 0.44; ADX 59.21 | The July 6 snapshot showed positive momentum, but the RSI and Williams %R readings also warned that the move was becoming extended. |
| Volume | About 0.77 million shares in the July 10 intraday snapshot | StockAnalysis displayed 767,951 shares at a July 10 intraday update. This was not treated as a final-day average, so volume confirmation remains a data gap. |
| Volatility | ATR(14) about $0.61; 52-week range $25.17 to $55.28 | Investing.com reported ATR(14) near $0.6062 on July 6. The wide annual range reflects event and biotech valuation risk. |
| Invalidation | Close below $50.98, then $45.65 | A decisive break below the recent low would weaken the near-term setup. A break below the 200-day average would require a broader fundamental review. |
ALKS AI trading strategy
The ALKS AI trading strategy below is a rules-based research framework, not personal advice. It links price action with LUMRYZ demand, proprietary product sales, debt repayment, operating cash flow, clinical milestones, patent events, and the CEO transition.
Watch for ALKS to reclaim the $52.97 to $54.03 area on stronger volume, then challenge the $55.28 high while revenue guidance, LUMRYZ execution, and cash flow remain intact.
A close below $50.98 reduces trend confidence. A close below $45.65 invalidates the medium-term technical trend and should trigger a review of earnings, debt, and pipeline assumptions.
If price tests the $50.98 to $51.72 band without a new fundamental problem, compare the drawdown with LUMRYZ prescription trends, proprietary net sales, debt reduction, and the base and bearish scenarios.
Do not treat a lower price as cheap if the market is repricing VIVITROL generic risk, clinical failure, Avadel integration problems, or a lasting debt burden.
Track total revenue, proprietary net sales, LUMRYZ revenue and patient growth, VIVITROL and LYBALVI trends, manufacturing and royalty revenue, gross to net adjustments, operating cash flow, term-loan balance, R&D spending, and alixorexton trial milestones.
The July 28, 2026 estimated earnings date is a scheduled review point. A revenue beat without improving cash generation or debt reduction would not by itself confirm the investment case.
Investment research summary
Customers and patients pay Alkermes for medicines that address difficult neurological and psychiatric conditions, often with long-acting or differentiated delivery. The company earns proprietary product sales from VIVITROL, ARISTADA, LYBALVI, and now LUMRYZ, plus royalties and manufacturing revenue from licensed products such as VUMERITY and long-acting INVEGA products.
The moat comes from formulation science, long-acting delivery systems, regulatory approvals, patents, manufacturing quality, and physician familiarity in specialist disease areas. It is not a network-effect moat. VIVITROL faces expected generic entry from 2027, while ARISTADA and LYBALVI have later stated patent expirations, so the moat must be renewed through innovation and execution.
The thesis fails if Avadel integration consumes more cash than expected, LUMRYZ cannot scale, new debt reduces flexibility, VIVITROL generic competition cuts pricing, royalty revenue falls faster, LYBALVI litigation or competition damages sales, or alixorexton fails in Phase 3. The 2026 GAAP loss shows that a growing revenue story can still produce volatile earnings.
Richard Pops has led Alkermes for decades and is scheduled to remain chairman after Blair Jackson becomes CEO on August 1, 2026. The Avadel deal added LUMRYZ and a sleep commercial organization, funded with about $775 million of cash and $1.525 billion of term loans due in 2031. Capital allocation is now judged by integration, debt repayment, clinical investment, and shareholder returns.
Neuroscience remains a large unmet-need market across addiction, schizophrenia, bipolar disorder, narcolepsy, and idiopathic hypersomnia. Alkermes has a credible position in sleep medicine through LUMRYZ and alixorexton, but it competes with established oxybate products, generic medicines, new antipsychotics, and better-funded pharmaceutical companies.
At $51.94, the stock was about 36.3x FY2025 diluted GAAP EPS and 18.2x FY2025 free cash flow per share. The audited three-year base scenario was near $53.30, close to the market price, which implies limited margin of safety unless LUMRYZ growth, debt reduction, or pipeline value exceeds the current expectations.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ALKS price | $51.94 closing price on July 10, 2026 | StockAnalysis market cap snapshot | July 12, 2026 |
| Market capitalization and shares | $8.69 billion reported; $8.66 billion from $51.94 x 166.68 million shares, 0.38% variance | StockAnalysis and financial_rigor.py | July 12, 2026 |
| FY2025 revenue | $1.476 billion, including $1.185 billion of product sales and $291.3 million of manufacturing and royalty revenue | Alkermes FY2025 10-K and StockAnalysis | July 12, 2026 |
| FY2025 GAAP net income and diluted EPS | $241.7 million net income and $1.43 diluted EPS | Alkermes FY2025 10-K and StockAnalysis | July 12, 2026 |
| FY2025 operating cash flow and free cash flow | $520.8 million operating cash flow and about $480.3 million free cash flow | Alkermes FY2025 10-K and StockAnalysis | July 12, 2026 |
| Q1 2026 financial results | $392.9 million revenue, $338.1 million proprietary net sales, and $66.5 million GAAP net loss | Alkermes Q1 2026 earnings release | July 12, 2026 |
| 2026 revenue guidance | $1.73 billion to $1.84 billion total revenue guidance | Alkermes Q1 2026 earnings materials | July 12, 2026 |
| Cash and debt after Avadel acquisition | About $538 million cash and investments at Q1 2026; $1.525 billion of term loans due in 2031 | Alkermes Q1 2026 earnings materials and Avadel transaction release | July 12, 2026 |
| Technical moving averages and momentum | 50-day SMA about $52.97, 200-day SMA about $45.65, RSI 65.478, MACD 0.44 | Investing.com technical snapshot | July 6, 2026 |
| Patent and generic risk | VIVITROL generic entry expected from 2027; latest stated U.S. patent expirations include 2039 for ARISTADA and 2041 for LYBALVI | Alkermes FY2025 10-K | July 12, 2026 |
This ALKS AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong if financial results, clinical data, regulation, patent disputes, competition, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
